Journal profile · ONCOLOGY
Cancer Drug Resistance
ISSN 2578-532X · OAE Publishing Inc. · UNITED STATES OF AMERICA · Continuous publication · Founded 2018
Cancer Drug Resistance: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 7.6 (journal website); fully open access; APC about USD 3,200; median 100 days to acceptance (101 articles, last 24 months); 63 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Cancer Drug Resistance is published by OAE Publishing Inc. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cancer Immunotherapy and Biomarkers, Cancer Cells and Metastasis and Cancer Genomics and Diagnostics, together about 22.7% of its articles. Its main subfields are Cancer Research and Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
Cancer Drug Resistance is a continuously published journal committed to the rapid publication of high quality, peer-reviewed, original researches. The journal publishes research articles, reviews, commentaries and letters on pharmacological aspects of drug resistance and its reversal, including drug design, drug delivery, drug distribution and cellular drug resistance. Molecular mechanisms of drug resistance also cover the cellular pharmacology of drug resistance such as influx and efflux pumps (including the ABC pumps), receptors and their ligands, cellular signaling pathways, drug activation and degradation (including Phase I and II metabolism), drug sequestration, target modification and DNA repair. Drug classes to be covered include DNA targeted drugs and antihormones as well as antibodies and protein kinase inhibitors. Both clinical and experimental aspects of drug resistance in cancer are included.
From the journal's Aims & Scope
Research area (LetPub): ONCOLOGY
Editor-in-chief Godefridus J. PetersPublisher website
Editorial board by country: 10 in mainland China (about 16%); most named United States 19, Italy 11, Mainland China 10, Netherlands 4, United Kingdom 3 (64 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Immunotherapy and BiomarkersMedicine8.7%
- Cancer Cells and MetastasisMedicine7.3%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology6.7%
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology6.3%
- Epigenetics and DNA MethylationBiochemistry, Genetics and Molecular Biology5.2%
- Cancer, Hypoxia, and MetabolismBiochemistry, Genetics and Molecular Biology5.2%
- Cancer therapeutics and mechanismsBiochemistry, Genetics and Molecular Biology4.9%
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology4.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher)
- 7.6Publisher website ·
- CiteScore 2026-06
- 10.3LetPub ·
- CiteScore (publisher)
- 10.3Publisher website ·
- SJR 2026-06
- 1.78LetPub ·
- SNIP 2026-06
- 1.12LetPub ·
- h-index
- 39OpenAlex ·
- i10-index
- 283OpenAlex ·
- 2-year mean citedness
- 5.9OpenAlex ·
- Self-citation rate
- 1.3%LetPub ·
- Share of gold OA articles
- 98.8%LetPub ·
Volume
- Articles per year
- 63LetPub ·
- Articles per year (publisher) 2027
- 2,027Publisher website ·
- Downloads per year (publisher)
- 943,852Publisher website ·
Articles by year OpenAlex count · 531 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 37 | 37 | 13 |
| 2025 | 63 | 63 | 383 |
| 2024 | 55 | 55 | 518 |
| 2023 | 51 | 51 | 990 |
| 2022 | 75 | 75 | 1,528 |
| 2021 | 65 | 65 | 1,187 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
100 daysMedian, submission to acceptance · P25–P75 71 days – 119 days
- Acceptance to online
- median 12 days (100 articles)
- Submission to online
- median 115 days
- Sample
- 101 articles with submission and acceptance dates (114 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Desk decision
- 9 daysPublisher website ·
- Submission to first decision
- 9 daysPublisher website ·
- Peer review
- Anonymous peer reviewLetPub
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessOpenAlex
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| LetPub | USD 2,800 | Yes | — | |
| Publisher website | USD 3,200 | — | — |
Other charges and waivers (author guidelines)
- Submission fee
- USD 3,200
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Open calls for papers2, by deadline
Publisher websiteWhat to prepare5 items from the author guidelines
- Keywords
- 3–8
- Reference style
- Numbered, in order of citation
- Suggested reviewers
- Optional
- Graphical abstract
- Required
- Cover letter
- Required
Article types accepted10, with length limits
- commentaryThe journal publishes Original Article, Review, Meta-Analysis, Commentary, etc. For more details about paper type, please refer to the following table. Manuscri…Length not stated
- editorialle Max 1,500 words; concise and focused Editorial Short opinion/news by Editors or publisher None None Flexible Max 1,000 words Letter to Editor Post-publicatio…main text ≤ 1,000 words
- letter to editorLetter to Editor Post-publication discussion/critiqueLength not stated
- meta-analysisThe journal publishes Original Article, Review, Meta-Analysis, Commentary, etc. For more details about paper type, please refer to the following table. Manuscri…Length not stated
- opinionThe journal publishes Original Article, Review, Meta-Analysis, Commentary, etc. For more details about paper type, please refer to the following table. Manuscri…Length not stated
- original articleThe journal publishes Original Article, Review, Meta-Analysis, Commentary, etc. For more details about paper type, please refer to the following table. Manuscri…Length not stated
- perspectiveThe journal publishes Original Article, Review, Meta-Analysis, Commentary, etc. For more details about paper type, please refer to the following table. Manuscri…Length not stated
- reviewThe journal publishes Original Article, Review, Meta-Analysis, Commentary, etc. For more details about paper type, please refer to the following table. Manuscri…Length not stated
- systematic reviewSystematic Review Critical analysis of studies using pre-specified methodologyLength not stated
- technical noteTechnical Note Short description of new or modified technique/procedure/deviceLength not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, Publication ethics, License & copyright, Open access, Trial registration / reporting guidelines
- AI use 2.3.3.4 AI and AI-assisted tools Statement
Disclosure of generative AI use in manuscript preparation is required. Model summary
Authors should disclose in their manuscript any use of AI and AI-assisted technologies. Declaring the use of these technologies supports transparency and trust between authors, readers, reviewers, editors, and contributors, and facilitates compliance with the terms of use of the relevant tool or technology.AI-generated text and references should be carefully checked to ensure accuracy and that the…
Source ↗Publisher website ·- Authorship 4. Authorship
Authorship credit of CDR journals should be solely based on substantial contributions to a published study, as specified in the following four criteria:1. Substantial contributions to the conception or design of the work, or the acquisition, analysis, or interpretation of data for the work;2. Drafting the work or revising it critically for important intellectual content;3. Final approval of the ve…
Source ↗Publisher website ·- Conflicts of interest 2.3.3.6 Conflicts of Interest
Authors must declare any potential conflicts of interest that may be perceived as inappropriately influencing the representation or interpretation of reported research results. If there are no conflicts of interest, please state "All authors declared that there are no conflicts of interest." in this section. Some authors may be bound by confidentiality agreements. In such cases, in place of itemiz…
Source ↗Publisher website ·- Data availability 2.3.3.3 Availability of Data and Materials
Data availability statement required in manuscripts. Model summary
In order to maintain the integrity, transparency and reproducibility of research records, authors should include this section in their manuscripts, detailing where the data supporting their findings can be found. Data can be deposited into data repositories or published as supplementary information in the journal. Authors who cannot share their data should state that the data will not be shared an…
Source ↗Publisher website ·- Publication ethics 2.3.3.7 Ethical Approval and Consent to Participate
Member of COPE; adheres to its Code of Conduct and Best Practice Guidelines. Model summary
Research involving human subjects, human material or human data must be performed in accordance with the Declaration of Helsinki and approved by an appropriate ethics committee. An informed consent to participate in the study should also be obtained from participants, or their parents or legal guardians for children under 16. A statement detailing the name of the ethics committee (including the re…
Source ↗Publisher website ·- License & copyright 1.2 Open Access and Copyright
Authors retain copyright under CC BY 4.0 and sign License to Publish. Model summary
The journal adopts Gold Open Access publishing model and distributes content under the Creative Commons Attribution 4.0 International License. Copyright is retained by authors. Please make sure that you are well aware of these policies.
Source ↗Publisher website ·- Open access 1.2 Open Access and Copyright
Gold Open Access under CC BY 4.0; authors retain copyright. Model summary
The journal adopts Gold Open Access publishing model and distributes content under the Creative Commons Attribution 4.0 International License. Copyright is retained by authors. Please make sure that you are well aware of these policies.
Source ↗Publisher website ·- Trial registration / reporting guidelines 3.1.5 Trial Registration
CDR requires all authors to register all relevant clinical trials that are reported in manuscripts submitted. CDR follows the World Health Organization (WHO)'s definition of clinical trials: "A clinical trial is any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes. Interventions i…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- OAE Publishing Inc.
- Country or region
- UNITED STATES OF AMERICA
- Language
- English
- Frequency
- Continuous publication
- Founded
- 2018
- ISSN
- 2578-532X
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- Peer review process ↗LetPub
- Editorial board ↗LetPub
FAQ
Frequently asked questions about Cancer Drug Resistance
What CAS zone is Cancer Drug Resistance in?
In the 2025 upgraded edition of the CAS Journal Ranking, Cancer Drug Resistance is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Cancer Drug Resistance?
The journal's website gives an impact factor of 7.6; this is the journal's own figure, as LetPub lists none for it; CiteScore 10.3, h-index 39.
How long does peer review take at Cancer Drug Resistance?
Based on the dates recorded on 101 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 100 days (interquartile range 71–119 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Cancer Drug Resistance?
According to the journal's author guidelines: Keywords: 3–8; Reference style: Numbered, in order of citation; Suggested reviewers: Optional; Graphical abstract: Required; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Cancer Drug Resistance based?
Of the 64 board members whose country the journal's board page names, 10 (about 16%) are in mainland China; the countries named most often are United States (19), Italy (11) and Mainland China (10). Counted from the institutions listed on the board page; for reference only.
Which databases index Cancer Drug Resistance?
According to LetPub and DOAJ records, Cancer Drug Resistance is indexed in ESCI and Scopus.
Is Cancer Drug Resistance open access, and what is the APC?
Cancer Drug Resistance is a fully open-access journal. APC about USD 3,200.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-24). Last updated: .